News | November 03, 2007

MASS Stent Trial Measures DES, BMS Risk Rates

November 4, 2007 – Drug-eluting stents to open blocked coronary arteries caused no more risks for death or heart attack than bare metal stents, according to a late-breaking outcomes trial presented at the American Heart Association’s Scientific Sessions 2007.

The Massachusetts stent (MASS Stent) trial compared death rates between patients who received drug-eluting stents and those who received bare metal stents. They reviewed records of all adults undergoing percutaneous coronary intervention (PCI) with stenting between April 1, 2003 and December 31, 2004 at all acute care non-U.S. governmental hospitals in Massachusetts. Using this criterion, they identified 20,654 patients from a state database with mandatory follow-up after PCI.

“This is the largest study of patients comparing drug-eluting stents and bare metal stents for long-term outcomes in the U.S.,” said Laura Mauri, M.D., principal investigator of the trial and assistant professor of medicine at Harvard Medical School and Brigham and Women’s Hospital in Boston, MA.

“It was previously established that drug-eluting stents make it less likely that patients will need repeat procedures within the first year after a stent procedure,” Mauri said. “What we were less certain about before this study was the long-term safety of drug-eluting stents compared to bare metal.”

Mauri adds that this trial has several benefits for addressing this issue. “It is a very large study with long-term follow up, it reflects contemporary U.S. practice – where most patients receive drug-eluting stents – and it includes all patients who were undergoing PCI – not just those who would have qualified for a randomized trial.”

Patients were followed up for at least two years after receiving a stent. Researchers compared the number of deaths, heart attacks, and revascularization procedures (either bypass surgery or another PCI) between the two groups. The adjusted incidence of mortality at two years was 9.4 percent for those with drug-eluting stents and 11.9 percent for those with bare metal stents.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The American Heart Association makes no representation or warranty as to their accuracy or reliability.

For more information: www.americanheart.org


Related Content

News | Cardiovascular Clinical Studies

February 21, 2024 — An 80-year-old woman from Frankenmuth, Michigan is the first Henry Ford Health structural heart ...

Home February 21, 2024
Home
News | Cardiovascular Clinical Studies

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
News | Cardiovascular Clinical Studies

January 3, 2024 — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce the completion of ...

Home January 03, 2024
Home
News | Cardiovascular Clinical Studies

December 19, 2023 — Peerbridge Health has announce the successful completion and findings of its prospective ...

Home December 19, 2023
Home
News | Cardiovascular Clinical Studies

December 14, 2023 — Published results of a large, national heart attack study show that patients with a life-threatening ...

Home December 14, 2023
Home
News | Cardiovascular Clinical Studies

December 11, 2023 — A world without cardiovascular disease (CVD) is possible, yet millions of lives are lost prematurely ...

Home December 11, 2023
Home
News | Cardiovascular Clinical Studies

December 8, 2023 — Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac ...

Home December 08, 2023
Home
News | Cardiovascular Clinical Studies

November 29, 2023 — Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of ...

Home November 29, 2023
Home
Subscribe Now